Related Experiment Video
Updated: Jun 24, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
[Henoch-Shönlein purpura]
Evangeline Pillebout1, Dominique Nochy, Eric Thervet
1Service de néphrologie et transplantation rénale, hôpital Saint-Louis, Paris, France. evangeline.pillebout@sls.aphp.fr
Nephrologie & Therapeutique
|April 7, 2009
Summary
Henoch-Shönlein purpura (HSP), an IgA vasculitis, affects small vessels and can lead to nephritis. While often mild in children, HSP can be severe in adults, with renal failure a significant long-term risk.
Area of Science:
- Immunology
- Rheumatology
- Nephrology
Background:
- Henoch-Shönlein purpura (HSP) is an immunoglobulin A (IgA) vasculitis impacting small blood vessels.
- It presents as a multi-system disease with characteristic cutaneous purpura, arthralgia, enteritis, and nephritis, the latter marked by mesangial proliferation and IgA deposition.
Purpose of the Study:
- To summarize the key features, pathogenesis, clinical manifestations, and outcomes of Henoch-Shönlein purpura.
- To highlight the differences in disease presentation and prognosis between pediatric and adult populations.
- To discuss current management strategies and the controversies surrounding treatment efficacy.
Main Methods:
- Literature review and synthesis of existing research on Henoch-Shönlein purpura.
- Analysis of clinical data regarding disease progression, complications, and treatment responses.
- Comparative evaluation of HSP in children versus adults.
Main Results:
- HSP pathogenesis involves IgA, with nephritis being a common and serious complication.
- While generally favorable in children, HSP in adults is rarer and associated with more severe outcomes.
- Gastrointestinal and renal involvement significantly influence short-term and long-term prognoses, respectively, with up to one-third progressing to end-stage renal failure.
Conclusions:
- HSP is an IgA-mediated vasculitis with variable severity and prognosis depending on age and organ involvement.
- Renal and gastrointestinal complications are critical determinants of patient outcomes.
- Management ranges from symptomatic treatment for mild cases to immunosuppressants for severe manifestations, though treatment efficacy remains debated.
Related Concept Videos
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:19Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
01:24Peptic Ulcer Disease II: Pathophysiology
Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
01:28Peptic Ulcer Disease II: Pathophysiology
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.